(225)Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings

PURPOSE: (225)Ac-PSMA-617 has demonstrated good anti-tumor effect as a treatment option for metastatic castration-resistant prostate cancer (mCRPC) patients. No study has previously assessed treatment outcome and survival following (225)Ac-PSMA-617 treatment of de novo metastatic hormone-sensitive p...

Descripción completa

Detalles Bibliográficos
Autores principales: Sathekge, Mike, Bruchertseifer, Frank, Vorster, Mariza, Lawal, Ismaheel O., Mokoala, Kgomotso, Reed, Janet, Maseremule, Letjie, Ndlovu, Honest, Hlongwa, Khanyi, Maes, Alex, Morgenstern, Alfred, Van de Wiele, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199874/
https://www.ncbi.nlm.nih.gov/pubmed/36864360
http://dx.doi.org/10.1007/s00259-023-06165-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199874/
https://www.ncbi.nlm.nih.gov/pubmed/36864360
http://dx.doi.org/10.1007/s00259-023-06165-9

Ejemplares similares